Syndax製藥 SNDX 深 滬
等待開盤 12-24 09:30:00 美东时间
21.70
+0.220
+1.02%
華盛通- 最 高22.73
- 今 開21.47
- 成交量 149.80万股
- 最 低 21.46
- 昨 收 21.48
- 總市值 18.69亿
- 52周最高 22.73
- 市盈率 靜 --
- 換手率 1.74%
- 52周最低 8.58
- 委 比 77.01%
- 總股本 8614.19万
- 歷史最高 29.86
- 量 比 0.94
- 振 幅 5.91%
- 歷史最低 3.39
- 每 手 1
- 風險率 2.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
Syndax Pharmaceuticals ( ($SNDX) ) has provided an announcement. On December 18...
12-20 06:09
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Syndax Pharmaceuticals' Revuforj® (revumenib), a first-in-class menin inhibitor, was awarded "Best New Drug" at the 2025 Scrip Awards, recognizing its groundbreaking science and therapeutic advances in treating relapsed or refractory acute leukemias with specific genetic mutations. Revuforj, approved for two patient populations in 2024 and 2025, received the award alongside its recent expanded approval for acute myeloid leukemia (AML) with NPM1 m...
12-12 12:00
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target
BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.
12-09 21:03
Syndax Pharma Highlights Key Revuforj Presentations Spanning Acute Leukemia Treatment Continuum Presented At ASH Annual Meeting
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts ––
12-08 19:52
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted 15,500 share purchase options to a new employee under its 2023 Inducement Plan, vesting over four years. The company, focused on innovative cancer therapies, has FDA-approved treatments including Revuforj and Niktimvo, and is advancing clinical trials.
12-03 21:01
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Syndax Pharmaceuticals announced that CEO Michael A. Metzger will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 4, 2025. The event will be accessible via live webcast and replay on the company's Investor website. Syndax, a biopharmaceutical company, focuses on advancing innovative cancer therapies, including FDA-approved Revuforj® and Niktimvo™, and is conducting multiple clinical trials.
12-01 12:00
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $35
Barclays analyst Etzer Darout maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $22 to $35.
11-24 22:37
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
